TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37772889

Group type: EXPERIMENTAL
Intervention: Sodium-glucose transporter 2 inhibitors and sparsentan as part of supportive care in patients with chronic kidney damage.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids in high-risk patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted-release budesonide, anti-B-cell strategies, and selective complement inhibition.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical parameters including degree of proteinuria, presence of persistent microscopic hematuria, rate of eGFR loss, mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, crescents score.
Number of subjects: 0
Study: 37772984

Group type: EXPERIMENTAL
Intervention: Stepped-care intervention
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 286
Study: 37773052

Group type: EXPERIMENTAL
Intervention: Tdap vaccination in PWWH
Number of subjects: 227

Group type: COMPARATOR
Intervention: Tdap vaccination in HIV-uninfected women
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Tdap vaccination in both groups
Number of subjects: 227
Study: 37773067

Group type: EXPERIMENTAL
Intervention: 1-h sepsis bundle initiation
Number of subjects: 18

Group type: COMPARATOR
Intervention: 3-h sepsis bundle initiation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Implementation strategy for both 1-h and 3-h bundles
Number of subjects: 18
Study: 37773184

Group type: EXPERIMENTAL
Intervention: Monovalent COVID-19 vaccines
Number of subjects: 252
Study: 37773189

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID vs 10 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate vs Tofacitinib
Number of subjects: 0
Study: 37773297

Group type: EXPERIMENTAL
Intervention: Active production of music
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 300
Study: 37773418

Group type: EXPERIMENTAL
Intervention: One repeated subgingival instrumentation (RSI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Two repeated subgingival instrumentations (RSI)
Number of subjects: 25
Study: 37773479

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation (MSCT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cultivated limbal epithelial transplantation (CLET)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MSCT
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CLET
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MSCT and CLET
Number of subjects: 23
Study: 37773497

Group type: EXPERIMENTAL
Intervention: High-cash gift ($333/mo, or $3996/y)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Low-cash gift ($20/mo, or $240/y)
Number of subjects: 1000
Study: 37773498

Group type: EXPERIMENTAL
Intervention: mHealth diabetes intervention (remote support from clinical pharmacists via video telehealth, health coach activities in person and via phone/text)
Number of subjects: 221

Group type: COMPARATOR
Intervention: waiting list control group (usual diabetes care for 1 year)
Number of subjects: 221

Group type: COMPARATOR
Intervention: waiting list control group (received mHealth intervention after 1 year)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: mHealth diabetes intervention (continued for intervention group)
Number of subjects: 221
Study: 37773600

Group type: EXPERIMENTAL
Intervention: Treatment (rehabilitation)
Number of subjects: 69
Study: 37773606

Group type: EXPERIMENTAL
Intervention: 5-factor model of the Maladaptive Personality and Interpersonal Schema (MPIS)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: MPIS questionnaire
Number of subjects: 234
Study: 37773616

Group type: EXPERIMENTAL
Intervention: Digital PrEP navigation and activation intervention (PrEPresent)
Number of subjects: 150
Study: 37773618

Group type: EXPERIMENTAL
Intervention: Supporting Transitions to Adulthood and Reducing Suicide (STARS) alongside Safety Planning Intervention (SPI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Safety Planning Intervention (SPI) alone
Number of subjects: 60
Study: 37773624

Group type: EXPERIMENTAL
Intervention: Mobile app intervention (IG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine preparations (CG)
Number of subjects: 70
Study: 37773627

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 37773633

Group type: EXPERIMENTAL
Intervention: Pharmacologic ascorbate (P-AscH-) combined with radiation and temozolomide
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pharmacologic ascorbate (P-AscH-)
Number of subjects: 55
Study: 37774014

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy
Number of subjects: 47
Study: 37774185

Group type: EXPERIMENTAL
Intervention: Lidocaine 2mg/kg with saline infusion (GL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg duloxetine (GD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous saline infusion (GC)
Number of subjects: 60
Study: 37774188

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine infusion (LDKI) at 0.1 mg/kg/h
Number of subjects: 318
Study: 37774508

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 weeks and capecitabine administered at 825 mg/m2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 60
Study: 37774646

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment to goal < 120 mm Hg
Number of subjects: 610

Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment to goal < 140 mm Hg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB) exposure
Number of subjects: 610
Study: 37774697

Group type: EXPERIMENTAL
Intervention: R-CHOP-X
Number of subjects: 128

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 128
Study: 37774729

Group type: EXPERIMENTAL
Intervention: Single-dose inactivated poliovirus vaccine (IPV)
Number of subjects: 502
Study: 37774842

Group type: EXPERIMENTAL
Intervention: Later stages of change toward meat reduction
Number of subjects: 25143

Group type: EXPERIMENTAL
Intervention: Initiated meat reduction
Number of subjects: 25143
Study: 37774841

Group type: EXPERIMENTAL
Intervention: Deuterated water consumption for 10 days before surgery
Number of subjects: 49
Study: 37774979

Group type: EXPERIMENTAL
Intervention: 8-week personalised activity plan
Number of subjects: 0
Study: 37775187

Group type: EXPERIMENTAL
Intervention: Stand-alone iCBT
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Guided iCBT
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control
Number of subjects: 279
Study: 37775282

Group type: EXPERIMENTAL
Intervention: Goal-directed financial incentives plus enhanced usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outcome-based financial incentives plus enhanced usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care alone
Number of subjects: 0
Study: 37775290

Group type: EXPERIMENTAL
Intervention: Endovascular renal denervation (RDN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Classic renal arteriography and sham RDN
Number of subjects: 80
Study: 37775297

Group type: EXPERIMENTAL
Intervention: Immediate oral semaglutide therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-year delay in oral semaglutide therapy
Number of subjects: 0
Study: 37775472

Group type: EXPERIMENTAL
Intervention: EUS-IREAD-assisted group
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 290
Study: 37775521

Group type: EXPERIMENTAL
Intervention: PHH-1V vaccine formulations 10 µg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PHH-1V vaccine formulations 20 µg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PHH-1V vaccine formulations 40 µg
Number of subjects: 30

Group type: COMPARATOR
Intervention: BNT162b2 (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PHH-1V
Number of subjects: 30
Study: 37775584

Group type: EXPERIMENTAL
Intervention: Gel containing green tea extract and hyaluronic acid applied 3 times a day for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle gel applied 3 times a day for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: No material placed in the donor area; only the clot kept in position by sutures
Number of subjects: 42
Study: 37775612

Group type: EXPERIMENTAL
Intervention: Chylomicron TG and ApoB-48 levels in individuals with type 2 diabetes
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ApoB-48 particles in VLDL in individuals with type 2 diabetes
Number of subjects: 11

Group type: COMPARATOR
Intervention: Fasting lipid profile
Number of subjects: 11
Study: 37775611

Group type: EXPERIMENTAL
Intervention: POWER2DM (e-health system)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 226
Study: 37775742

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 1303
Study: 37775744

Group type: EXPERIMENTAL
Intervention: Fuzuloparib 100 mg bid plus apatinib 500 mg qd
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fuzuloparib plus apatinib
Number of subjects: 52
Study: 37776001

Group type: EXPERIMENTAL
Intervention: SPAN-intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 61
Study: 37776194

Group type: EXPERIMENTAL
Intervention: Individualized heparin-protamine titration (IHPT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional heparinization and reversal (cACT)
Number of subjects: 132
Study: 37776210

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention focusing on exercise, diet, cognitive/social stimulation, and cardiovascular health
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention focusing on exercise, diet, cognitive/social stimulation, and cardiovascular health (different intensity and accountability)
Number of subjects: 2000
Study: 37776214

Group type: EXPERIMENTAL
Intervention: Cumulative hsCRP level quartiles (1-4)
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Cumulative times of high hsCRP levels (0-3 times)
Number of subjects: 1281
Study: 37776235

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (infliximab and adalimumab)
Number of subjects: 324
Study: 37776326

Group type: EXPERIMENTAL
Intervention: CD19/22 dual-targeted CAR-T cell combined with tislelizumab (anti-PD-1 antibody)
Number of subjects: 16
Study: 37776354

Group type: EXPERIMENTAL
Intervention: Extensive protein hydrolysate formula (EHF)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Cow milk formula (CMF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both EHF and CMF
Number of subjects: 141
Study: 37776390

Group type: EXPERIMENTAL
Intervention: C. albicans inoculum (3.10)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: C. albicans virulence expression
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid composition
Number of subjects: 26
Study: 37776478

Group type: EXPERIMENTAL
Intervention: Long-acting intramuscular cabotegravir plus rilpivirine combination treatment every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIN questionnaire
Number of subjects: 0
Study: 37776502

Group type: EXPERIMENTAL
Intervention: Anti-3-
Number of subjects: 36

Group type: COMPARATOR
Intervention: Contrast-enhanced MRI
Number of subjects: 36
Study: 37776510

Group type: EXPERIMENTAL
Intervention: Telerehabilitation using virtual reality glasses for 10 sessions over 5 weeks
Number of subjects: 12
Study: 37776695

Group type: EXPERIMENTAL
Intervention: Copper-NiTi archwires
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tubular coaxial-NiTi archwires
Number of subjects: 31
Study: 37776754

Group type: EXPERIMENTAL
Intervention: Tablet-based neuroplasticity-oriented sensorimotor training (EG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tablet-based relaxation training (CG)
Number of subjects: 48
Study: 37776872

Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy, administered as four 28-day cycles with daratumumab at 16 mg/kg intravenously on days 1, 8, 15, and 22, and carfilzomib at 56 mg/m2.
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy.
Number of subjects: 123
Study: 37776876

Group type: EXPERIMENTAL
Intervention: TV005 vaccine
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 37776879

Group type: EXPERIMENTAL
Intervention: Chlorfenapyr-PY LLINs
Number of subjects: 4587

Group type: EXPERIMENTAL
Intervention: PBO-PY LLINs
Number of subjects: 4587

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen-PY LLINs
Number of subjects: 4587

Group type: COMPARATOR
Intervention: Standard PY LLINs
Number of subjects: 4587
Study: 37776953

Group type: EXPERIMENTAL
Intervention: YK-029A 200 mg/d (dose-expansion phase)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: YK-029A (all doses during dose-escalation)
Number of subjects: 108
Study: 37777018

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (200 mg loading dose/50 mg daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (100 mg/50 mg daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (50 mg daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (30 mg daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (10 mg daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 37777256

Group type: EXPERIMENTAL
Intervention: mTICI 3
Number of subjects: 226

Group type: COMPARATOR
Intervention: mTICI 2b
Number of subjects: 226
Study: 37777255

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm-guided remote ECG monitoring with Zenicor-ECG device
Number of subjects: 1955
Study: 37777270

Group type: EXPERIMENTAL
Intervention: External oblique intercostal plane block (EOIPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard multimodal analgesia (Control)
Number of subjects: 80
Study: 37777515

Group type: EXPERIMENTAL
Intervention: Dopamine synthesis capacity measured by PET imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine receptor availability measured by PET imaging
Number of subjects: 0
Study: 37777600

Group type: EXPERIMENTAL
Intervention: High tendency of emotional overeating
Number of subjects: 184

Group type: COMPARATOR
Intervention: Low tendency of emotional overeating
Number of subjects: 184
Study: 37777684

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 100
Study: 37777738

Group type: EXPERIMENTAL
Intervention: MR-guided SBRT in 5 fractions (37.5 Gy over 10-14 days)
Number of subjects: 136

Group type: COMPARATOR
Intervention: MR-guided SBRT in 2 fractions (25 Gy over 7-10 days)
Number of subjects: 136
Study: 37777743

Group type: EXPERIMENTAL
Intervention: Empagliflozin (early treatment < 24 hours after PCI)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Empagliflozin (intermediate treatment 24 to < 48 hours after PCI)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Empagliflozin (late treatment 48 to 72 hours after PCI)
Number of subjects: 231
Study: 37777806

Group type: EXPERIMENTAL
Intervention: AD(LATE-NC+) cases with comorbid TDP-43 pathology
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Tau biosensor cell line treated with sarkosyl-insoluble, brain-derived homogenates from AD(LATE-NC+) cases
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: TDP-43 pathology
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 37777832

Group type: EXPERIMENTAL
Intervention: Xevinapant 200 mg/day on days 1-14 of a 3-week cycle
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Xevinapant 200 mg/day
Number of subjects: 62
Study: 37777827

Group type: EXPERIMENTAL
Intervention: Tremelimumab combined with anti-PD-L1 durvalumab and chemotherapy
Number of subjects: 1605
Study: 37777947

Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomographic Angiography (CTA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomographic Angiography (CTA) with Fractional Flow Reserve (FFR)
Number of subjects: 50
Study: 37778085

Group type: EXPERIMENTAL
Intervention: Mechanical temporal summation at the knee
Number of subjects: 90
Study: 37778226

Group type: EXPERIMENTAL
Intervention: Truncated dual antiplatelet therapy (DAPT)
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Peripheral vascular disease
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Congestive heart failure
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Renal insufficiency/failure
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Predicted bleeding risk <4%
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Predicted bleeding risk ≥4%
Number of subjects: 2009
Study: 37778356

Group type: EXPERIMENTAL
Intervention: Gradual, flexible antipsychotic reduction
Number of subjects: 253

Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 253
Study: 37778358

Group type: EXPERIMENTAL
Intervention: Efgartigimod (10 mg/kg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 37778363

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted nirmatrelvir
Number of subjects: 209

Group type: COMPARATOR
Intervention: No study drug
Number of subjects: 209
Study: 37778526

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 829
Study: 37778613

Group type: EXPERIMENTAL
Intervention: Neurofilament Light Chain (NfL) at 24 hours
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Glial Fibrillary Acidic Protein (GFAP) at 48 hours
Number of subjects: 82

Group type: COMPARATOR
Intervention: NfL and GFAP compared to Neuron Specific Enolase (NSE) at 48 hours
Number of subjects: 82
Study: 37778954

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy with systematic sampling (strategy 4)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy alone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MRI and MRI-targeted biopsy
Number of subjects: 144
Study: 37779885

Group type: EXPERIMENTAL
Intervention: Quantitative pupillometry (qPLR <4% and NPi ≤2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined quantitative pupillometry with neuron-specific enolase (NSE >60 μg L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated quantitative pupillometry
Number of subjects: 0
Study: 37779919

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) plus radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irinotecan (IRIN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan silicasome nanoparticles
Number of subjects: 0
Study: 37780046

Group type: EXPERIMENTAL
Intervention: Interdisciplinary Intervention with a team consisting of a pediatrician, psychologist, and physiotherapist.
Number of subjects: 677
Study: 37780052

Group type: EXPERIMENTAL
Intervention: CytoSorb therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (historical cohort)
Number of subjects: 17
Study: 37780064

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 207
Study: 37780065

Group type: EXPERIMENTAL
Intervention: Temporal processing tele-intervention (TPT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional language remediation (CLR)
Number of subjects: 95
Study: 37780074

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment (discontinued)
Number of subjects: 37

Group type: COMPARATOR
Intervention: REGN1103 (dupilumab surrogate)
Number of subjects: 37
Study: 37780126

Group type: EXPERIMENTAL
Intervention: Bilateral overground gait-slip perturbation training (blocks of eight non-paretic and paretic slips followed by mixed blocks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (single non-paretic and paretic slip in random order)
Number of subjects: 65
Study: 37780234

Group type: EXPERIMENTAL
Intervention: Reduced-dose pneumococcal conjugate vaccine schedules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37780560

Group type: EXPERIMENTAL
Intervention: Palliative care consultation (PC), 32 patients received PC consultation (30 were virtual)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Palliative care consultation (PC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No palliative care consultation (Control group)
Number of subjects: 39
Study: 37780620

Group type: EXPERIMENTAL
Intervention: T2DMH patients (T2DM patients with hypertension)
Number of subjects: 92

Group type: COMPARATOR
Intervention: T2DM patients (without hypertension)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 92
Study: 37780701

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 500
Study: 37780770

Group type: EXPERIMENTAL
Intervention: Hybrid transvaginal natural orifice transluminal endoscopic surgery (hvNOTES)
Number of subjects: 0
Study: 37781111

Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 0
Study: 37781132

Group type: EXPERIMENTAL
Intervention: Folic acid dosage of 0.8 mg
Number of subjects: 1567

Group type: EXPERIMENTAL
Intervention: Folic acid dosages ranging from 0 mg to 2.4 mg
Number of subjects: 1567

Group type: COMPARATOR
Intervention: Folic acid dosages of 0, 0.4, 0.6, 0.8, 1.2, 1.6, 2.0 mg to 2.4 mg
Number of subjects: 1567
Study: 37781156

Group type: EXPERIMENTAL
Intervention: Prediction tool and communication skills training
Number of subjects: 31
Study: 37781158

Group type: EXPERIMENTAL
Intervention: Ibrutinib and bortezomib combination therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance after combination therapy
Number of subjects: 58